• CR Sanjiu reported a net income of 1.36 billion yuan for the first quarter.
• The company earned revenue totalling 7.29 billion yuan in the same period.
• The stock has an overwhelmingly positive outlook with 23 buy recommendations and no holds or sells.
China Resources Sanjiu Medical & Pharma on Smartkarma
Analysts on Smartkarma have varying views on China Resources Sanjiu Medical & Pharma. Xinyao (Criss) Wang‘s bearish outlook in the report titled “China Resources Sanjiu (000999.CH) – 2023 Results Below Expectations; Short-Term Headwinds Remain” highlights that Sanjiu’s 2023 performance fell short of expectations due to challenges in the TCM injection business and anti-corruption measures. Despite a high dividend payout ratio, the performance growth outlook for 2024 is anticipated to be lower than that of 2023.
Conversely, Xinyao (Criss) Wang‘s bullish perspective in the report “China Healthcare Weekly (Nov.24) – Gold Content Of License-Out Deals, NRDL Pricing Levels, CR Sanjiu” emphasizes that the upfront payment in licensing deals signifies their true value. The stability in NRDL prices for innovative drugs and the focus on upfront payments rather than milestone payments are key considerations. However, challenges such as anti-corruption impact and weak TCM formula granules business performance could put pressure on Sanjiu’s 2023 second half results.
A look at China Resources Sanjiu Medical & Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is showing promising signs for its long-term outlook based on the Smartkarma Smart Scores. With a strong momentum score of 5, the company is demonstrating significant positive price trends and investor interest. This suggests a potential for continued growth and market outperformance in the future.
Additionally, China Resources Sanjiu Medical & Pharma received high scores in dividend, growth, and resilience, indicating a solid financial foundation and potential for future expansion and stability. While the value score is slightly lower at 3, the overall outlook for the company seems positive, supported by its diverse business operations in the healthcare and pharmaceutical sectors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
